The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells

The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we...

Full description

Bibliographic Details
Main Authors: Juan Sebastian Yakisich, Neelam Azad, Vivek Kaushik, Anand K. V. Iyer
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2019/6254269
id doaj-7d05f3b2a01049b5b3c22b17d4786808
record_format Article
spelling doaj-7d05f3b2a01049b5b3c22b17d47868082020-11-25T01:04:23ZengHindawi LimitedStem Cells International1687-966X1687-96782019-01-01201910.1155/2019/62542696254269The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer CellsJuan Sebastian Yakisich0Neelam Azad1Vivek Kaushik2Anand K. V. Iyer3School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, VA 23668, USASchool of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, VA 23668, USASchool of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, VA 23668, USASchool of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, VA 23668, USAThe biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we investigated in vitro the anticancer activity of MET and BUF alone or in combination with 2-deoxy-D-glucose (2-DG) and WZB-117 (WZB), which are a glycolysis and a GLUT-1 inhibitor, respectively, in H460 human lung cancer cells growing under three different culture conditions with varying degrees of stemness: (1) routine culture conditions (RCCs), (2) floating lung tumorspheres (LTSs) that are enriched for stem-like cancer cells, and (3) adherent cells under prolonged periods (8-12 days) of serum starvation (PPSS). These cells are highly resistant to conventional anticancer drugs such as paclitaxel, hydroxyurea, and colchicine and display an increased level of stemness markers. As single agents, MET, BUF, 2-DG, and WZB-117 potently inhibited the viability of cells growing under RCCs. Both MET and BUF showed a strong synergistic effect when used in combination with 2-DG. A weak potentiation was observed when used with WZB-117. Under RCCs, H460 cells were more sensitive to MET and BUF and WZB-117 compared to nontumorigenic Beas-2B cells. While LTSs were less sensitive to each single drug, both MET and BUF in combination with 2-DG showed a strong synergistic effect and reduced cell viability to similar levels compared to the parental H460 cells. Adherent cells growing under PPSS were also less sensitive to each single drug, and MET and BUF showed a strong synergistic effect on cell viability in combination with 2-DG. Overall, our data demonstrates that the combination of BGs with either 2-DG or WZB-117 has “broad-spectrum” anticancer activities targeting cells growing under a variety of cell culture conditions with varying degrees of stemness. These properties may be useful to overcome the chemoresistance due to intratumoral heterogeneity found in lung cancer.http://dx.doi.org/10.1155/2019/6254269
collection DOAJ
language English
format Article
sources DOAJ
author Juan Sebastian Yakisich
Neelam Azad
Vivek Kaushik
Anand K. V. Iyer
spellingShingle Juan Sebastian Yakisich
Neelam Azad
Vivek Kaushik
Anand K. V. Iyer
The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
Stem Cells International
author_facet Juan Sebastian Yakisich
Neelam Azad
Vivek Kaushik
Anand K. V. Iyer
author_sort Juan Sebastian Yakisich
title The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_short The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_full The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_fullStr The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_full_unstemmed The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_sort biguanides metformin and buformin in combination with 2-deoxy-glucose or wzb-117 inhibit the viability of highly resistant human lung cancer cells
publisher Hindawi Limited
series Stem Cells International
issn 1687-966X
1687-9678
publishDate 2019-01-01
description The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we investigated in vitro the anticancer activity of MET and BUF alone or in combination with 2-deoxy-D-glucose (2-DG) and WZB-117 (WZB), which are a glycolysis and a GLUT-1 inhibitor, respectively, in H460 human lung cancer cells growing under three different culture conditions with varying degrees of stemness: (1) routine culture conditions (RCCs), (2) floating lung tumorspheres (LTSs) that are enriched for stem-like cancer cells, and (3) adherent cells under prolonged periods (8-12 days) of serum starvation (PPSS). These cells are highly resistant to conventional anticancer drugs such as paclitaxel, hydroxyurea, and colchicine and display an increased level of stemness markers. As single agents, MET, BUF, 2-DG, and WZB-117 potently inhibited the viability of cells growing under RCCs. Both MET and BUF showed a strong synergistic effect when used in combination with 2-DG. A weak potentiation was observed when used with WZB-117. Under RCCs, H460 cells were more sensitive to MET and BUF and WZB-117 compared to nontumorigenic Beas-2B cells. While LTSs were less sensitive to each single drug, both MET and BUF in combination with 2-DG showed a strong synergistic effect and reduced cell viability to similar levels compared to the parental H460 cells. Adherent cells growing under PPSS were also less sensitive to each single drug, and MET and BUF showed a strong synergistic effect on cell viability in combination with 2-DG. Overall, our data demonstrates that the combination of BGs with either 2-DG or WZB-117 has “broad-spectrum” anticancer activities targeting cells growing under a variety of cell culture conditions with varying degrees of stemness. These properties may be useful to overcome the chemoresistance due to intratumoral heterogeneity found in lung cancer.
url http://dx.doi.org/10.1155/2019/6254269
work_keys_str_mv AT juansebastianyakisich thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT neelamazad thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT vivekkaushik thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT anandkviyer thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT juansebastianyakisich biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT neelamazad biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT vivekkaushik biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT anandkviyer biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
_version_ 1725198483262013440